These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 32061385)

  • 1. ADVANCE database characterisation and fit for purpose assessment for multi-country studies on the coverage, benefits and risks of pertussis vaccinations.
    Sturkenboom M; Braeye T; van der Aa L; Danieli G; Dodd C; Duarte-Salles T; Emborg HD; Gheorghe M; Kahlert J; Gini R; Huerta-Alvarez C; Martín-Merino E; McGee C; de Lusignan S; Picelli G; Roberto G; Tramontan L; Villa M; Weibel D; Titievsky L
    Vaccine; 2020 Dec; 38 Suppl 2():B8-B21. PubMed ID: 32061385
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ADVANCE system testing: Can safety studies be conducted using electronic healthcare data? An example using pertussis vaccination.
    Weibel D; Dodd C; Mahaux O; Haguinet F; De Smedt T; Duarte-Salles T; Picelli G; Tramontan L; Danieli G; Correa A; McGee C; Martín-Merino E; Huerta-Alvarez C; Berencsi K; Emborg HD; Bollaerts K; Bauchau V; Titievsky L; Sturkenboom M
    Vaccine; 2020 Dec; 38 Suppl 2():B38-B46. PubMed ID: 31677946
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ADVANCE system testing: Can coverage of pertussis vaccination be estimated in European countries using electronic healthcare databases: An example.
    Emborg HD; Kahlert J; Braeye T; Bauwens J; Bollaerts K; Danieli G; Duarte-Salles T; Glismann S; Huerta-Alvarez C; de Lusignan S; Martín-Merino E; McGee C; Correa A; Tramontan L; Weibel D; Sturkenboom M
    Vaccine; 2020 Dec; 38 Suppl 2():B22-B30. PubMed ID: 31677953
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Advance system testing: Vaccine benefit studies using multi-country electronic health data - The example of pertussis vaccination.
    Tin Tin Htar M; de Ridder M; Braeye T; Correa A; McGee C; de Lusignan S; Duarte-Salles T; Huerta-Alvarez C; Martín-Merino E; Tramontan L; Danieli G; Picelli G; van der Maas N; Berencsi K; Arnheim-Dahlström L; Heininger U; Emborg HD; Weibel D; Bollaerts K; Sturkenboom M
    Vaccine; 2020 Dec; 38 Suppl 2():B31-B37. PubMed ID: 31677949
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ADVANCE system testing: Benefit-risk analysis of a marketed vaccine using multi-criteria decision analysis and individual-level state transition modelling.
    Bollaerts K; Ledent E; de Smedt T; Weibel D; Emborg HD; Danieli G; Duarte-Salles T; Huerta-Alvarez C; Martín-Merino E; Picelli G; Tramontan L; Sturkenboom M; Bauchau V
    Vaccine; 2020 Dec; 38 Suppl 2():B65-B75. PubMed ID: 31677947
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ADVANCE system testing: Estimating the incidence of adverse events following pertussis vaccination in healthcare databases with incomplete exposure data.
    Dodd C; de Ridder M; Weibel D; Mahaux O; Haguinet F; de Smedt T; de Lusignan S; McGee C; Duarte-Salles T; Emborg HD; Huerta-Alvarez C; Martín-Merino E; Picelli G; Berencsi K; Danieli G; Sturkenboom M
    Vaccine; 2020 Dec; 38 Suppl 2():B47-B55. PubMed ID: 32280043
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Age-specific vaccination coverage estimates for influenza, human papillomavirus and measles containing vaccines from seven population-based healthcare databases from four EU countries - The ADVANCE project.
    Braeye T; Emborg HD; Llorente-García A; Huerta C; Martín-Merino E; Duarte-Salles T; Danieli G; Tramontan L; Weibel D; McGee C; Villa M; Gini R; Lehtinen M; Titievsky L; Sturkenboom M
    Vaccine; 2020 Apr; 38(16):3243-3254. PubMed ID: 32171573
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ADVANCE: Towards near real-time monitoring of vaccination coverage, benefits and risks using European electronic health record databases.
    Bollaerts K; de Smedt T; McGee C; Emborg HD; Villa M; Alexandridou M; Duarte-Salles T; Gini R; Bartolini C; de Lusignan S; Tin Tin Htar M; Titievsky L; Sturkenboom M; Bauchau V
    Vaccine; 2020 Dec; 38 Suppl 2():B76-B83. PubMed ID: 31677951
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Which strategy for pertussis vaccination today?
    Girard DZ
    Paediatr Drugs; 2002; 4(5):299-313. PubMed ID: 11994035
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quantifying outcome misclassification in multi-database studies: The case study of pertussis in the ADVANCE project.
    Gini R; Dodd CN; Bollaerts K; Bartolini C; Roberto G; Huerta-Alvarez C; Martín-Merino E; Duarte-Salles T; Picelli G; Tramontan L; Danieli G; Correa A; McGee C; Becker BFH; Switzer C; Gandhi-Banga S; Bauwens J; van der Maas NAT; Spiteri G; Sdona E; Weibel D; Sturkenboom M
    Vaccine; 2020 Dec; 38 Suppl 2():B56-B64. PubMed ID: 31677950
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Control of pertussis in the world.
    Galazka A
    World Health Stat Q; 1992; 45(2-3):238-47. PubMed ID: 1462658
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pertussis vaccination in infancy lowers the incidence of pertussis disease and the rate of hospitalisation after one and two doses: analyses of 10 years of pertussis surveillance.
    Nilsson L; Lepp T; von Segebaden K; Hallander H; Gustafsson L
    Vaccine; 2012 May; 30(21):3239-47. PubMed ID: 22094282
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and efficacy of acellular pertussis vaccine in Japan, evaluated by 23 years of its use for routine immunization.
    Kuno-Sakai H; Kimura M
    Pediatr Int; 2004 Dec; 46(6):650-5. PubMed ID: 15660862
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A safety and immunogenicity comparison of 12 acellular pertussis vaccines and one whole-cell pertussis vaccine given as a fourth dose in 15- to 20-month-old children.
    Pichichero ME; Deloria MA; Rennels MB; Anderson EL; Edwards KM; Decker MD; Englund JA; Steinhoff MC; Deforest A; Meade BD
    Pediatrics; 1997 Nov; 100(5):772-88. PubMed ID: 9346976
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative Epidemiologic Characteristics of Pertussis in 10 Central and Eastern European Countries, 2000-2013.
    Heininger U; André P; Chlibek R; Kristufkova Z; Kutsar K; Mangarov A; Mészner Z; Nitsch-Osuch A; Petrović V; Prymula R; Usonis V; Zavadska D
    PLoS One; 2016; 11(6):e0155949. PubMed ID: 27257822
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pertussis in Mexico from 2000 to 2019: A real-world study of incidence, vaccination coverage, and vaccine effectiveness.
    Sánchez-González G; Luna-Casas G; Mascareñas C; Macina D; Vargas-Zambrano JC
    Vaccine; 2023 Sep; 41(41):6105-6111. PubMed ID: 37661533
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Strategy for pertussis prevention in the World Health Organization's European Region.
    Dittmann S
    J Infect Dis; 1996 Nov; 174 Suppl 3():S291-4. PubMed ID: 8896532
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pertussis vaccine effectiveness among children 6 to 59 months of age in the United States, 1998-2001.
    Bisgard KM; Rhodes P; Connelly BL; Bi D; Hahn C; Patrick S; Glodé MP; Ehresmann KR;
    Pediatrics; 2005 Aug; 116(2):e285-94. PubMed ID: 16061582
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Whooping cough and pertussis vaccine: a comparison of risks and benefits in Britain during the period 1968-83.
    Stewart GT
    Dev Biol Stand; 1985; 61():395-405. PubMed ID: 3835080
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Potential use of Western Australia’s mandatory Midwives Notification System for routinely monitoring antenatal vaccine coverage.
    Regan AK; Effler PV; Thomson C; Mak DB
    Commun Dis Intell (2018); 2019 Jun; 43():. PubMed ID: 31203587
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.